QT Prolongation, Avoid CYP3A4 Inhibitors
- Torimefene has been shown to prolong the QTc interval in a dose- and concentration-related manner. Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death.
- Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia.
- Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided
Patient Counseling Information
Updated January 2018